# ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting

Source: https://onco.cc/trials/nct04241315/  
OnCo record `nct04241315` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pafolacianine in Lung cancer, run by On Target Laboratories, LLC, completed.

## Summary

ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting is a phase 3 interventional study registered as NCT04241315 by On Target Laboratories, LLC, with 112 participants recorded, started 2020-03-26 and reaching its primary completion in 2021-10-07. Interventions recorded: OTL38 for Injection, Near infrared camera imaging system. Conditions recorded: Lung Neoplasms, Lung Cancer.

Linked to the drug Pafolacianine because the registry names it among its interventions and Lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04241315
- Phase: 3
- Setting: A Phase 3, Randomized,Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules
- Sponsor: On Target Laboratories, LLC
- Enrolled: 112

## Sources

- ClinicalTrials.gov NCT04241315: https://clinicaltrials.gov/study/NCT04241315

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- drugs: [Pafolacianine](https://onco.cc/drugs/pafolacianine/)
- companies: [On Target Laboratories](https://onco.cc/companies/on-target-laboratories/)

---
JSON: https://onco.cc/api/v1/entities/nct04241315.json